EXTON, Pa.--(BUSINESS WIRE)--Melior Discovery, Inc. announced today that it has acquired all of the assets of Biolucidation, LLC and appointed its scientific founder, Dr. Gregory Gatto as Senior Director of Behavioral Pharmacology for Melior Discovery Inc.
Dr. Gatto is a highly accomplished preclinical pharmacology expert with deep experience in the area of drug abuse liability. He has accumulated over 30 years of preclinical pharmacology research experience and over 15 years of pharmaceutical R&D experience in the area of psychiatric disease and cognition. As the scientific founder at Biolucidation, Dr. Gatto built an organization that specialized in drug abuse liability studies with a focus on integrating research principles of substance abuse derived from preclinical and human abuse liability models. Prior, to founding Biolucidation, Dr. Gatto was Senior Director of Pharmacology at Targacept, Inc. where he played an instrumental role in creating clinical stage assets from preclinical R&D stage projects. Dr. Gatto also led projects to reposition clinical assets for new indications which is fitting with Melior’s core mission of drug repositioning.
With this development, Melior is significantly expanding its complement of preclinical pharmacology capabilities. Dr. Gatto will incorporate his sophisticated expertise into Melior’s unique drug evaluation capabilities and high-throughput in vivo phenotypic screening. Dr. Gatto’s expertise will particularly augment Melior’s capabilities around evaluation of drug-candidates in a host of central nervous system disorders. In addition to Melior’s extensive battery of in vivo models, Dr. Gatto’s expertise will now expand Melior’s capabilities to include certain aspects of drug liability evaluation--specifically abuse liability.
“We are excited about the added capabilities that Greg brings to our team at Melior,” said Andrew Reaume PhD, CEO, Melior Discovery. “His addition to the Melior team significantly deepens our pharmacology bench.”
About Melior Discovery, Inc.
Melior Discovery is leading the transformation of pharmaceutical drug repositioning with its unique theraTRACE® platform of multiplexed in vivo models. Melior is using this capability to build an internal pipeline of development candidates. Melior Discovery also partners with pharmaceutical and biopharmaceutical companies to expand their drug development pipelines by using the theraTRACE® platform, and individual animal models, in conjunction with the Company’s in-depth in vivo pharmacology expertise.
